Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Velasco

Showing results (451-460 of 469) with videos related to

Pageof 47
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsH Cortes-Funes, C Gomez, R Rosell, et al.
Plos One|September 8, 2017
SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functionsLei L Chen, Jing Zhu, Jonathan Schumacher, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|June 22, 2010
Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trialH von Hertzen, N T M Huong, G Piaggio, et al.
Scientific Reports|August 8, 2024
Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63L Martínez-Campelo, A Blanco-Verea, T López-Fernández, et al.
Carcinogenesis|August 10, 2013
The highly prevalent BRCA2 mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple originsMar Infante, Mercedes Durán, Alberto Acedo, et al.
Molecular Cancer Therapeutics|December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activityRobert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
Breast Cancer Research and Treatment|November 5, 2011
Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancerAna Blanco, Miguel de la Hoya, Judith Balmaña, et al.
Cancer Research|January 24, 2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell ExpansionXuanmao Jiao, Marco A Velasco-Velázquez, Min Wang, et al.
Plos One|August 13, 2013
Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer casesAna Blanco, Miguel de la Hoya, Ana Osorio, et al.
Cancer Research|September 3, 2004
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumorsLei L Chen, Jonathan C Trent, Elsie F Wu, et al.
Pageof 47

Showing results (451-460 of 469) with videos related to

Sort By:
Pageof 47
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsH Cortes-Funes, C Gomez, R Rosell, et al.
Plos One|September 8, 2017
SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functionsLei L Chen, Jing Zhu, Jonathan Schumacher, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|June 22, 2010
Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trialH von Hertzen, N T M Huong, G Piaggio, et al.
Scientific Reports|August 8, 2024
Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63L Martínez-Campelo, A Blanco-Verea, T López-Fernández, et al.
Carcinogenesis|August 10, 2013
The highly prevalent BRCA2 mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple originsMar Infante, Mercedes Durán, Alberto Acedo, et al.
Molecular Cancer Therapeutics|December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activityRobert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.
Breast Cancer Research and Treatment|November 5, 2011
Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancerAna Blanco, Miguel de la Hoya, Judith Balmaña, et al.
Cancer Research|January 24, 2018
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell ExpansionXuanmao Jiao, Marco A Velasco-Velázquez, Min Wang, et al.
Plos One|August 13, 2013
Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer casesAna Blanco, Miguel de la Hoya, Ana Osorio, et al.
Cancer Research|September 3, 2004
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumorsLei L Chen, Jonathan C Trent, Elsie F Wu, et al.
Pageof 47